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Abstract
Background: The optimal time to initiate renal replacement therapy (RRT) in intensive care unit (ICU) patients with
acute kidney injury (AKI) is unclear. We examined the impact of early RRT on long-term mortality, risk of chronic
kidney disease (CKD), and end-stage renal disease (ESRD).
Methods: This cohort study included all adult patients treated with continuous RRT in the ICU at Aarhus University
Hospital, Skejby, Denmark (2005–2015). Data were obtained from a clinical information system and population-
based registries. Early treatment was defined as RRT initiation at AKI stage 2 or below, and late treatment was
defined as RRT initiation at AKI stage 3. Inverse probability of treatment (IPT) weights were computed from propensity
scores. The IPT-weighted cumulative risk of CKD (estimated glomerular filtration rate < 60 ml/minute/1.73 m2), ESRD,
and mortality was estimated and compared using IPT-weighted Cox regression.
Results: The mortality, CKD, and ESRD analyses included 1213, 303, and 617 patients, respectively. The 90-day mortality
in the early RRT group was 53.6% compared with 46.0% in the late RRT group (HR 1.24, 95% CI 1.03–1.48). The 90-day
to 5-year mortality was 37.7% and 41.5% in the early and late RRT groups, respectively (HR 0.95, 95% CI
0.70–1.29). The 5-year risk of CKD was 35.9% in the early RRT group and 44.9% in the late RRT group (HR 0.74, 95% CI
0.46–1.18). The 5-year risk of ESRD was 13.3% in the early RRT group and 16.7% in the late RRT group (HR 0.79, 95% CI
0.47–1.32).
Conclusions: Early initiation was associated with increased 90-day mortality. In patients surviving to day 90, early
initiation was not associated with a major impact on long-term mortality or risk of CKD and ESRD. Despite potential
residual confounding due to the observational design, our findings do not support that early RRT initiation is superior
to late initiation.
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Background
Acute kidney injury (AKI) occurs in 39–57% of intensive
care unit (ICU) patients, and 6–14% of ICU patients are
treated with renal replacement therapy (RRT) [1–4].
Patients with RRT-treated AKI have a 90-day mortality
of 50–60% and a 5-year risk of end-stage renal disease
(ESRD) of > 10% [5–8]. The optimal time to initiate RRT
remains unclear [9]. There is a theoretical rationale for
early initiation of RRT, such as improved control of fluid
balance, electrolytes, and acid-base status. However, a
treatment strategy of earlier initiation is accompanied by
the risk of exposing patients who might have recovered
without RRT to RRT and treatment-related complica-
tions [10].
Authors of meta-analyses of primarily observational stud-
ies have found early RRT initiation to be associated with re-
duced short-term mortality compared with late RRT
initiation [11, 12]. However, the majority of included studies
had methodological limitations, such as small sample sizes
or inadequate control of confounding. Results of random-
ized controlled trials (RCTs) are conflicting, but authors of
meta-analyses of pooled data have observed no difference
in short-term mortality or RRT dependency [13, 14].
To our knowledge, only two observational studies have
assessed mortality beyond day 90, and none have exam-
ined the impact of timing of RRT on risk of chronic
kidney disease (CKD) and ESRD [15, 16]. To address
this gap in the literature, we conducted a cohort study
to examine the impact of early RRT in ICU patients on
5-year risk of CKD, ESRD, and mortality.
Methods
Study population and setting
This cohort study included all patients aged 15 years or
older who were treated with continuous RRT in the 13-bed
ICU at Aarhus University Hospital, Skejby, Denmark, from
January 1st, 2005, to January 1st, 2015. Patients were admit-
ted from departments of infectious diseases, cardiology,
nephrology, urology, gynecology, thoracic surgery, and vas-
cular surgery. The ICU is a university-affiliated, highly spe-
cialized referral unit treating cardiac transplant patients,
among others, and performing extracorporeal membrane
oxygenation (ECMO). Patients treated with RRT were iden-
tified in a clinical information system (CIS) database used
in the ICU (Picis; Picis Inc., Wakefield, MA, USA). The CIS
database contains detailed, real-time, electronically regis-
tered data on, among others, treatment with vasopressors
and inotropes, mechanical ventilation, hemodynamics, and
RRT treatment. Additionally, it contains manually regis-
tered data on weight and urine output. All patients were
treated using a PRISMA continuous RRT system (GAM-
BRO DASCO S.p.A., Medolla, Italy) with a prescribed efflu-
ent dose of 30 ml/kg/h. Continuous venovenous
hemodiafiltration was used in the vast majority (>90%) of
patients. Until March 2014, heparin was the standard antic-
oagulation method, and citrate was used thereafter.
The Danish health care system is tax-funded and
provides free and universal health care for all Danish
citizens. Every citizen has a Danish civil registration
(CPR) number assigned at birth or immigration [17].
Through the CPR number, deterministic individual-
level linkage between clinical and administrative
databases is possible. To ensure information on pre-
admission morbidity and follow-up, we included only
patients with a Danish CPR number and who had
residency in Denmark [17]. We considered only pa-
tients with newly developed severe renal impairment
and therefore excluded patients with existing ESRD at
ICU admission.
Timing of renal replacement therapy
The AKI stage was assessed by using the Kidney Disease:
Improving Global Outcomes (KDIGO) AKI criteria for
plasma creatinine and urine output (measured as volume
in ml/minute/kg; whichever value gave patients the
highest stage) (Table 1) [18]. The creatinine measure-
ments were obtained from a laboratory database [19].
The database contains information on every blood test
taken during in- and outpatient visits to public or pri-
vate hospitals or submitted by general practitioners in
the central and northern regions of Denmark (for NPU
[Nomenclature for Properties and Units] codes, see
Additional file 1: Table S1). The creatinine ratio was
calculated using the latest creatinine measurement 24 h
before RRT initiation divided by the baseline creatinine.
Baseline creatinine was estimated as the mean of all
creatinine measurements from outpatient clinics or visits
to the general practitioner from 1 year to 7 days before
ICU admission [20]. For patients without outpatient cre-
atinine measurements, the baseline was imputed with the
four-variable Modification of Diet in Renal Disease
(MDRD) equation (assuming an estimated glomerular
filtration rate [eGFR] of 75 ml/minute/1.73 m2 and Cauca-
sian race), as suggested by the KDIGO AKI guideline [18].
The urine output was obtained from the CIS, requiring
at least 6 h of observation time in accordance with the
KDIGO AKI criteria (Table 1) [18]. To compute urine
output per kilogram of body weight, we used the average
weight during the ICU stay. Patients who could not be
evaluated for their urine output owing to < 6 h of obser-
vation time, no diuresis measurements in the specified
time period before RRT, or no recorded weight, were
assigned an AKI stage based on the creatinine measure-
ments only.
Timing of RRT was defined as early if treatment was
initiated at AKI stage 2 or below, including patients not
meeting the AKI criteria. Late initiation of RRT was de-
fined as AKI stage 3 at the time of RRT initiation.
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Chronic kidney disease, end-stage renal disease, and
mortality
CKD was defined as at least two eGFR measurements
< 60 ml/minute/1.73 m2 separated by > 90 days [21].
The eGFR was estimated from creatinine measurements
using the four-variable MDRD equation (assuming Cauca-
sian race) using only outpatient blood samples to avoid in-
clusion of creatinine measurements performed during
hospitalization with acute illness.
ESRD was defined as treatment with chronic RRT or
kidney transplant > 90 days after initiation of RRT in the
ICU and was obtained from the Danish National Patient
Registry (DNPR). The DNPR contains information on all
nonpsychiatric admissions since 1977 and outpatient
and emergency visits since 1995. The data include the
type of admission (elective or acute), procedures per-
formed, and up to 20 diagnoses given by the physician at
discharge, using the Tenth Revision of the International
Classification of Diseases since 1994 (Additional file 1:
Table S1) [22]. With CKD and ESRD as outcomes of
interest, we included both patients who had renal recov-
ery and later developed the outcome and patients with-
out renal recovery.
Time of death was obtained from the Danish Civil
Registration system. The registry is updated daily and
contains complete information since 1968 on vital sta-
tus, emigration, and residency [17].
Covariates
Information on preadmission morbidity 10 years before ICU
admission was obtained from the DNPR and included diag-
noses assigned after an in- or outpatient visit, except visits to
the emergency department to increase validity [22]. We thus
included previous diagnoses of renal disease, diabetes (types
1 and 2), congestive heart failure, myocardial infarction, cere-
brovascular disease, chronic pulmonary disease, liver disease,
periphery vascular disease, malignant solid tumors, lymph-
oma, leukemia, and metastatic solid tumors, all of which are
considered accurate [22]. Using the DNPR, patients were
categorized as nonsurgical, elective noncardiac surgical, acute
noncardiac surgical, elective cardiac surgical, and acute
cardiac surgical, dependent on their type of admission and
surgery performed within a period from 24 h before ICU ad-
mission until RRT initiation [23]. Information on mechanical
ventilation was obtained from the DNPR. Using information
from the laboratory database and the CIS, we computed the
patients’ Sequential Organ Failure Assessment (SOFA) score
on the basis of worst values 24 h before initiation of RRT,
not considering the Glasgow Coma Scale score and renal
function (i.e., creatinine level) [24]. Missing or not measured
physiological parameters included in the SOFA score were
considered normal. The latest potassium and sodium mea-
surements within 24 h before RRT initiation were obtained
from the laboratory database [19].
Statistical analysis
The patient’s characteristics, including demography,
other ICU treatments, laboratory values, and time of
treatment, were tabulated for the early and late initiation
groups. Continuous variables were presented as means
with standard deviations (SD) or medians with inter-
quartile intervals (IQI), as appropriate. Categorical vari-
ables were presented as frequencies and percentages.
We followed patients until outcome of interest, emigra-
tion, 5 years from RRT initiation, or censoring on Janu-
ary 1st, 2016, whichever came first. Owing to differences
in follow-up requirements and outcome definitions, we
performed an analysis for each outcome: CKD, ESRD,
and death. By definition, chronic renal impairment
should last > 90 days [21]. Therefore, we included only
patients who survived until day 90 when we examined
the impact on CKD and ESRD. Furthermore, to examine
the impact of early and late RRT on the risk of CKD, we
included only patients having residency in a Danish re-
gion covered by the laboratory database (i.e., the central
and northern regions of Denmark) and without evidence
of existing renal disease. Prior renal disease was defined
as at least two outpatient eGFR measurements < 60 ml/
minute/1.73 m2 at least 90 days apart during the year
before ICU admission or a diagnosis of any renal disease
before admission [19].
To adjust for potential confounders, propensity scores
were estimated using a multivariable logistic regression
model including all the prespecified characteristics
presented for each cohort [25]. The included variables
are presented in Table 2 for the mortality analysis, with
the CKD and ESRD analyses presented in Additional file
2: Table S2 and Additional file 3: Table S3, respectively.
Continuous variables were included in the model with a
restricted cubic spline function with four knots. From
the propensity scores, we computed inverse probability
of treatment (IPT) weights; when these weights are
Table 1 Definition of early and late renal replacement therapy
Group KDIGO
stage
Creatinine Urine output
Early RRT Patients not meeting AKI
criteria
1 1.5–1.9 times baseline
or ≥ 26.5 μmol/L
(0.3 mg/dl) increase in
creatinine within 48 h
<0.5 ml/kg/h
for 6–12 h
2 2.0–2.9 times baseline <0.5 ml/kg/h
for > 12 h
Late RRT 3 3.0 times baseline or
creatinine ≥ 354 μmol/L
(4.0 mg/dl)a
<0.3 ml/kg/h
for > 24 h or
anuria for ≥ 12 h
Abbreviations: AKI Acute kidney injury, KDIGO Kidney Disease: Improving Global
Outcomes, RRT Renal replacement therapy
aSatisfies AKI criteria as well
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applied to a population, they create a pseudo-population
in which exposure status is independent of measured co-
variates [26, 27]. The covariate balance in the full and
IPT-weighted cohorts was evaluated with standard mean
differences [26]. For each outcome, we estimated the
IPT-weighted cumulative risk. With ESRD and CKD as
outcomes of interest, we accounted for death as a com-
peting risk. The HRs were estimated using a crude and
IPT-weighted Cox proportional hazards regression with
the 95% CI estimated using a robust variance estimator.
The assumption of proportional hazards was checked
graphically by log(-log) plots. As sensitivity analyses, we
repeated the analyses for each outcome after exclusion
of patients treated with ECMO in addition to RRT
during ICU admission. Additionally, we performed a
fifth-percentile asymmetrical trim to remove the poten-
tial influence of unmeasured confounding in the tails of
the propensity score distributions [28].
Analyses were performed using the Stata version 14.1
statistical software package (StataCorp LP, College Station,
TX, USA). The study was approved by the Danish Data
Protection Agency (record number 2015-57-0002, Aarhus
University record number 2016-051-000001-432).
Results
Descriptive results
In the 10-year study period, 1369 adult patients were
treated with RRT. We excluded 69 patients with previ-
ous ESRD, 31 with residency outside Denmark, and 14
who could not be linked to the DNPR. We had to ex-
clude 42 patients because of missing information on la-
boratory values prior to RRT initiation. This gave us a
study population of 1213 patients (Fig. 1). The total
follow-up time was 1994 person-years. The median time
from ICU admission to RRT initiation was 18.9 (IQI
8.3–35.2) h in the early group compared with 32.8 (IQI
7.8–79.8) h in the late group.
Characteristics of the full and IPT-weighted cohort
with mortality as an outcome are presented in Table 2.
In the full cohort, early and late RRT were initiated
in 621 (51.2%) and 592 (48.8%) patients, respectively.
The groups had similar age and sex distributions;
however, early initiators had a higher SOFA score (5.5
vs. 4.8) and were more likely to have received acute
cardiac surgery (30.3% vs. 22.3%). A higher proportion
of patients in the late group were treated in the
beginning of the study period (2005–2006). In the
IPT-weighted cohort, demographics, use of other
organ-supportive treatments, laboratory values, pread-
mission morbidities, and year of treatment were simi-
larly distributed in both groups. The most frequent
preadmission morbidities were renal disease, congest-
ive heart failure, and vascular disease.
Measured baseline creatinine was available in 829
(68.3%) patients. Patients without measured baseline cre-
atinine were equally distributed between both treatment
groups, and they were younger and had less preadmis-
sion morbidity than those with baseline creatinine (Add-
itional file 4: Table S4). AKI stage was assessed by urine
output and creatinine criteria in 682 (56.2%) patients
and by creatinine criteria only in 531 (43.8%) patients.
Mortality
In the crude analysis, 90-day mortality was 52.5% and
45.6% in the early and late groups, respectively (Table 3).
The corresponding HR was estimated as 1.24 (95% CI
1.06–1.46) in the early group compared with the late
group. In the IPT-weighted analysis, the 90-day mortal-
ity was 53.6% in the early group and 46.0% in late group
(Table 3 and Fig. 2). This corresponds to a HR of 1.24
(95% CI 1.03–1.48). In the crude analysis, 90-day to 5-
year mortality was 36.1% in the early group and 42.6% in
the late group. The corresponding HR was estimated to
0.89 (95% CI 0.68–1.17). In the IPT-weighted analysis,
the 90-day to 5-year mortality was 37.7% in the early
group and 41.5% in the late group with a corresponding
HR of 0.95 (95% CI 0.70–1.29).
Chronic kidney disease
With CKD as outcome, 303 patients were eligible for the
analysis (Fig. 1). The patients’ characteristics were
equally distributed between the early and late groups
after IPT weighting (Additional file 2: Table S2). Of
the 141 patients who initiated RRT early, 119 (84.4%)
had 2 or more outpatient creatinine measurements
after hospital discharge compared with 146 (90.1%) of
the 162 patients who initiated RRT late. In the crude
analysis, the 5-year risk of CKD was 43.6% and 45.0%
in the early and late groups, respectively (Table 3). This cor-
responds to a HR of 0.95 (95% CI 0.67–1.34). In the IPT-
weighted analysis, the 5-year risk of CKD was 35.9% in the
early group and 44.9% in the late group with a correspond-
ing HR of 0.74 (95% CI 0.46–1.18) (Table 3 and Fig. 3).
End-stage renal disease
With ESRD as outcome, the analysis included 617
patients (Fig. 1). After IPT weighting, the patients’ char-
acteristics were equally distributed between the early
and late groups (Additional file 3: Table S3). In the crude
analysis, the 5-year risk of ESRD was 13.9% and 14.4% in
the early and late groups, respectively (Table 3). This
corresponds to a HR of 0.96 (95% CI 0.62–1.48). In the
IPT-weighted analysis, the 5-year risk of ESRD was
13.3% in the early group and 16.7% in the late group
(Table 3 and Fig. 4). This corresponds to a HR of 0.79
(95% CI 0.47–1.32).
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Sensitivity analyses
After exclusion of 149 patients treated with ECMO during
ICU admission, the results were similar (Additional file 5:
Table S5). Furthermore, after a fifth percentile asym-
metrical trimming, the results of the analyses with
mortality and CKD as outcomes of interest were similar
(Additional file 5: Table S5), although for the ESRD out-
come, the HR was attenuated from 0.79 (95% CI 0.47–
1.32) to 1.02 (95% CI 0.59–1.75), indicating some treat-
ment heterogeneity and possible residual confounding.
Table 2 Characteristics for the full and inverse probability of treatment-weighted cohort with mortality as outcome
Full cohort IPT-weighted cohort
Early RRT (n = 621) Late RRT (n = 592) SMD Early RRT (n = 621) Late RRT (n = 592) SMD
Demographics
Age, years, median (IQI) 67.7 (58.5–75.3) 69.0 (59.3–75.8) −0.09 68.1 (59.5–76.6) 68.7 (58.1–75.5) 0.03
Male sex, n (%) 419 (65.5) 419 (70.8) −0.11 425 (68.5) 401 (67.7) 0.02
Surgical status, n (%)
Nonsurgical 229 (36.9) 281 (47.5) −0.22 261 (42.1) 248 (42.0) −0.02
Noncardiac surgery, elective 37 (6.0) 47 (7.9) −0.08 42 (6.7) 43 (7.3) −0.02
Noncardiac surgery, acute 67 (10.8) 66 (11.1) −0.01 67 (10.8) 65 (11.0) −0.00
Cardiac surgery, elective 100 (16.1) 66 (11.1) 0.14 84 (13.5) 74 (12.5) 0.03
Cardiac surgery, acute 188 (30.3) 132 (22.3) 0.18 167 (26.8) 161 (27.3) −0.01
SOFA score, mean (SD) 5.5 (2.4) 4.8 (2.5) 0.29 5.2 (2.5) 5.2 (2.5) 0.01
ICU treatments, n (%)
Vasopressors or inotropes 555 (89.4) 491 (82.9) 0.19 543 (87.4) 513 (86.6) 0.02
Mechanical ventilation 475 (76.5) 420 (70.9) 0.13 460 (74.0) 441 (74.5) −0.01
Extracorporeal membrane oxygenation 84 (13.5) 40 (6.8) 0.23 67 (10.7) 65 (11.0) −0.01
Laboratory values
Creatinine, baseline, μmol/L, median (IQI) 94.9 (82.0–117.0) 90.7 (73.7–102.2) 0.19 93.2 (76.8–115.0) 92.0 (76.8–111.7) 0.01
Potassium, mmol/L, median (IQI) 4.4 (3.9–5.0) 4.5 (4.1–5.1) −0.17 4.4 (4.0–5.0) 4.5 (4.0–5.0) −0.04
Sodium, mmol/L, mean (SD) 139.3 (7.0) 138.8 (7.2) 0.06 138.9 (7.1) 138.8 (7.0) 0.00
Preadmission morbidity, n (%)
Renal disease 178 (28.7) 208 (35.1) −0.14 198 (31.9) 188 (31.8) 0.00
Diabetes 101 (16.3) 107 (18.1) −0.05 108 (17.4) 104 (17.5) −0.00
Congestive heart disease 180 (29.0) 120 (20.3) 0.20 161 (25.9) 153 (25.9) −0.00
Myocardial infarction 154 (24.8) 136 (23.0) 0.04 149 (24.0) 148 (25.0) −0.02
Cerebrovascular disease 80 (12.9) 86 (14.5) −0.05 83 (13.3) 76 (12.9) 0.01
Chronic pulmonary disease 113 (18.2) 90 (15.2) 0.08 101 (16.3) 92 (15.6) 0.02
Liver disease 21 (3.4) 23 (3.9) −0.03 22 (3.6) 21 (3.5) 0.00
Vascular disease 172 (27.7) 161 (27.2) 0.01 180 (29.1) 164 (27.7) 0.03
Tumor 68 (11.0) 95 (16.0) −0.15 85 (13.7) 81 (13.7) −0.00
Lymphoma 9 (1.4) 6 (1.0) 0.04 8 (1.3) 9 (1.5) −0.01
Leukemia 7 (1.1) 5 (0.8) 0.03 6 (0.9) 7 (1.1) −0.02
Metastasis 16 (2.6) 17 (2.9) −0.02 16 (2.5) 17 (2.9) −0.03
Year of treatment, n (%)
2005–2006 95 (15.3) 149 (25.2) −0.25 121 (19.5) 115 (19.4) −0.04
2007–2008 101 (16.3) 120 (20.3) −0.10 112 (18.0) 106 (18.0) −0.00
2009–2010 141 (22.7) 93 (15.7) 0.18 119 (19.1) 119 (20.1) −0.03
2011–2012 158 (25.4) 94 (15.9) 0.24 132 (21.3) 124 (20.9) 0.01
2013–2014 126 (20.3) 136 (23.0) −0.07 138 (22.1) 128 (21.7) 0.01
Abbreviations: ICU Intensive care unit, IPT Inverse probability of treatment, IQI Interquartile interval, RRT Renal replacement therapy, SMD Standard mean
difference, SOFA Sequential Organ Failure Assessment, SD Standard deviation
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Discussion
Using data collected from high-quality clinical and adminis-
trative registries, we found no clear evidence that early initi-
ation of RRT in ICU patients was associated with improved
long-term clinical outcomes. Early initiation of RRT was
not associated with decreased long-term risk of CKD or
ESRD. Early initiation was associated with increased short-
term mortality but not with long-term mortality. Despite
the use of advanced methods, we cannot rule out the influ-
ence of residual confounding.
Fig. 1 Flowchart of eligible patients included in the analyses. CKD Chronic kidney disease, DNPR Danish National Patient Registry, ESRD End-stage
renal disease, RRT Renal replacement therapy
Table 3 Crude and inverse probability of treatment-weighted cumulative risks and hazard ratios
Crude analysis IPT-weighted analysis
Early RRT, % Late RRT, % HR (95% CI) Early RRT, % Late RRT, % HR (95% CI)
Mortality, n = 1213
0 to 90 days 52.5 45.6 1.24 (1.06–1.46) 53.6 46.0 1.24 (1.03–1.48)
90 days to 5 years 36.1 42.6 0.89 (0.68–1.17) 37.7 41.5 0.95 (0.70–1.29)
0 to 5 years 69.7 68.8 NA 71.1 68.4 NA
CKD, n = 303
90 days to 5 years 43.6 45.0 0.95 (0.67–1.34) 35.9 44.9 0.74 (0.46–1.18)
ESRD, n = 617
90 days to 5 years 13.9 14.4 0.96 (0.62–1.48) 13.3 16.7 0.79 (0.47–1.32)
Abbreviations: CI Confidence interval, CKD Chronic kidney disease, ESRD End-stage renal disease, NA Not applicable, IPT Inverse probability of treatment, RRT Renal
replacement therapy
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Existing studies
Until recently, existing studies on timing of RRT in ICU
patients with AKI were mainly observational, with few
RCTs conducted. Researchers in observational studies
have used a wide array of parameters to define timing,
such as blood urea nitrogen, creatinine, urine output,
fluid overload, traditional indications for RRT (e.g.,
hyperkalemia), time from ICU admission, time from AKI
diagnosis, and according to the RIFLE (risk, injury,
failure, loss, end-stage renal disease) criteria [11]. The
results derived from these observational studies on
short-term mortality are conflicting, but after pooling
the results of both observational and RCTs, meta-
analyses in general favor early RRT initiation [11, 12].
However, because of the heterogeneity in definitions of
early and late RRT and the methodological limitations of
included studies, the results should be interpreted with
caution. Wierstra et al. found that low-quality studies
(mainly observational studies) favored early initiation
(OR 0.47, 95% CI 0.34–0.65; early compared with late);
however, in high-quality studies (mainly RCTs), early
RRT did not statistically significantly reduce mortality
(OR 0.67, 95% CI 0.38–1.15) [11].
In the majority of conducted RCTs, investigators have
defined timing according to the presence of absolute
indications [13]. In the recent multicenter AKIKI
(Artificial Kidney Initiation in Kidney Injury) trial, 619
patients with AKI stage 3 who required mechanical ven-
tilation, catecholamine infusion, or both were random-
ized either to immediate RRT (early) or to treatment
being withheld until absolute indications developed
(late) [29]. The authors observed no difference in 60-day
mortality or RRT dependency. These findings are sup-
ported by meta-analyses including only RCTs on timing
of RRT [13, 14]. The single-center ELAIN (Early versus
Late Initiation of Renal-Replacement Therapy in Critic-
ally Ill Patients with Acute Kidney Injury) trial is the only
RCT in which researchers have observed a lower short-term
mortality with early initiation [30]. The authors randomized
231 patients with AKI stage 2 and plasma neutrophil
gelatinase-associated lipocalin > 150 ng/ml to early RRT
treatment (initiated within 8 h of diagnosis of AKI stage 2)
or to late RRT treatment (within 12 h of AKI stage 3 diagno-
sis or if absolute indications developed). The authors found a
reduced 90-day mortality with early initiation (HR 0.66, 95%
CI 0.45–0.97); however, no difference in RRT dependency at
day 90 was found.
No RCTs and few observational studies have assessed
outcomes beyond day 90. Evaluating long-term out-
comes is important because AKI is associated with a sig-
nificant impact on long-term morbidity and mortality
[8]. Researchers in two studies have examined the asso-
ciation between timing of RRT and mortality beyond day
90. Park et al. classified 607 patients as early or late
Fig. 2 Inverse probability of treatment-weighted cumulative mortal-
ity for 0 to 90 days, HR 1.24 (95% CI 1.03–1.48); for 90 days to 5 years,
HR 0.95 (95% CI 0.70–1.29). RRT Renal replacement therapy
Fig. 3 Inverse probability of treatment-weighted cumulative risk of
chronic kidney disease for 90 days to 5 years, HR 0.74 (95% CI 0.46–1.18).
CKD Chronic kidney disease, RRT Renal replacement therapy
Fig. 4 Inverse probability of treatment-weighted cumulative risk of
end-stage renal disease for 90 days to 5 years, HR 0.79 (95% CI 0.47–
1.32). ESRD End-stage renal disease, RRT Renal replacement therapy
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initiators based on the median 6-h urine output [15].
Carl et al. defined 147 nonsurgical ICU patients as early
or late initiators if their blood urea nitrogen was below
or above 100 mg/dl (35 mmol/L), respectively [16]. In
contrast to the present study, both of these previous
studies demonstrated that early initiation was associated
with reduced mortality; however, the interpretation of
these studies was hampered by lack of control for im-
portant potential confounders.
Strengths and limitations
Our study has some limitations that need to be consid-
ered when interpreting the results. First, we were able to
include only patients who were treated with RRT. The
lack of patients in the comparison group with AKI stage
2 (and thus potentially early initiators) who regained
their renal function without RRT may have introduced
bias. Second, baseline creatinine was available for 68.2%
of the patients, with the remainder being estimated with
the MDRD equation. This method may lead to slight
over- and underestimation of the AKI stage [31–33].
Because the proportion of patients without available
baseline creatinine were equally distributed between
early and late RRT, any misclassification of AKI stage
would most likely bias the estimates toward the null.
Examination of patients with missing baseline creatinine
showed that they were younger and had less comorbid-
ity. Therefore, we found that imputation using the
MDRD equation was reasonable. Third, we were able to
obtain information on urine output in slightly more than
half of the patients, with the remainder being staged
only according to their creatinine ratio. This may have
led to misclassification of the early and late initiation
groups and may have biased the estimates. Fourth,
because CKD can be present without symptoms, our
outcome is dependent upon patients having an out-
patient blood samples with creatinine taken. A large pro-
portion of the patients included in the CKD analysis had
two or more outpatient measurements, and we therefore
find it plausible that we identified the vast majority of
patients with CKD. Also, we have no reason to believe
that AKI stage at initiation of RRT would impact health
care vigilance after discharge, and therefore it cannot ex-
plain the observed results. Last, as with all observational
studies, there still is a risk of residual confounding; how-
ever, we were able to adjust for demographic characteris-
tics, detailed data on other ICU treatments, and
laboratory values at initiation of RRT.
Conclusions
Our findings do not support that early RRT initiation is
superior to late initiation. Although early RRT was asso-
ciated with increased short-term mortality, we found no
association between timing and long-term outcomes.
This study extends current knowledge on timing of RRT
and short-term mortality by providing estimates of the
impact on long-term mortality and risk of CKD and
ESRD.
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